Elotuzumab
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Elotuzumab: From Multiple Myeloma to Indolent Plasma Cell Myeloma
One-Sentence Summary
Elotuzumab is an anti-SLAMF7 (CS1) immunostimulatory monoclonal antibody originally developed for relapsed/refractory multiple myeloma (used in combination with lenalidomide/pomalidomide + dexamethasone). The TxGNN model predicts it may be effective for Indolent (Smoldering) Plasma Cell Myeloma, but this direction is currently supported by only 1 indirectly-related clinical trial and 2 non-RCT publications.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Multiple Myeloma (relapsed/refractory, per known mechanism-of-action description; no EU marketing authorization on file) |
| Predicted New Indication | Indolent Plasma Cell Myeloma |
| TxGNN Prediction Score | 98.62% |
| Evidence Level | L3 |
| EU Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not on file in the standard drug record (DrugBank MOA field: Data Gap), but supplementary rationale data indicates Elotuzumab is an anti-SLAMF7 (CS1) immunostimulatory monoclonal antibody. It works by activating NK-cell-mediated antibody-dependent cellular cytotoxicity (ADCC) and by directly binding SLAMF7, a surface antigen highly expressed on malignant plasma cells. Its established use is in active multiple myeloma, typically combined with lenalidomide/pomalidomide and dexamethasone.
Indolent (smoldering) plasma cell myeloma sits on the same disease spectrum as active multiple myeloma — it is the asymptomatic, early-stage counterpart in which clonal plasma cells already express SLAMF7 but have not yet caused end-organ damage. Mechanistically, targeting SLAMF7 in this earlier stage is plausible, since the target antigen itself does not depend on disease activity.
However, mechanistic plausibility does not equal clinical readiness: the standard of care for indolent/smoldering myeloma is observation rather than active treatment, so introducing an immunotherapy here raises a clinical-management question that goes beyond simple repositioning of an approved drug to an adjacent indication.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT03019666 | Phase 1 | Completed | 39 | Trial of NAM-expanded haploidentical/mismatched-related-donor NK cells (± short-course IL-2) in relapsed/refractory multiple myeloma and NHL; NK cells are the effector population for elotuzumab’s ADCC mechanism, but the trial title does not name elotuzumab as a study drug, so relevance is indirect (Grade B) rather than direct evidence of elotuzumab use in indolent myeloma. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 27610224 | 2016 | Review | F1000Research | Discusses revised diagnostic criteria under which former “ultra-high-risk smoldering myeloma” is now reclassified as myeloma requiring treatment, and reviews evolving triplet-therapy response rates. |
| 31413971 | 2017 | Cohort | Journal of Patient-Centered Research and Reviews | Pilot study of vaccination practice patterns in multiple myeloma patients within a large health system, evaluated via EMR/data analytics. |
EU Market Information
Elotuzumab currently has no EU marketing authorization on file (market status: Not Marketed, 0 authorizations recorded).
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Immunotherapy (anti-SLAMF7 monoclonal antibody, ADCC-based mechanism) |
| Myelosuppression Risk | Please refer to the SmPC warnings and precautions |
| Emetogenicity Classification | Please refer to the SmPC warnings and precautions |
| Monitoring Items | Please refer to the SmPC warnings and precautions |
| Handling Protection | Please refer to the SmPC warnings and precautions |
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence for elotuzumab in indolent plasma cell myeloma consists of a single indirectly-related Phase 1 trial (no elotuzumab arm confirmed) and two non-RCT publications (L3), with no dedicated trial evaluating elotuzumab specifically in this population. A blocking data gap on TFDA/label safety information (warnings, contraindications) currently prevents even an initial S1 safety screen, and the drug has no EU marketing authorization. Separately, indolent/smoldering myeloma’s standard of care is observation, making active pharmacologic intervention itself a contested clinical question independent of repurposing merits.
To proceed, the following is needed:
- Elotuzumab SmPC/label safety data (warnings, contraindications, drug interactions) — currently a blocking gap
- Confirmed detailed mechanism-of-action documentation from DrugBank or equivalent source
- A dedicated clinical trial evaluating elotuzumab specifically in smoldering/indolent multiple myeloma, rather than inferring relevance from an NK-cell-therapy trial in active disease
- Clarification of EU regulatory/marketing status and pathway, since the drug is currently unmarketed in this dataset
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.